List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
16 May 2024 | By Drug Target Review
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint…
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
A specialised drug-loaded nanoparticle, which can cross the blood-brain barrier, shrunk both breast tumours and breast cancer cells.
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several…
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
